A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS

Heterologous prime-boost immunisation with RTS,S/AS02A and the poxvirus MVA-CS was evaluated in 18 healthy malaria-naïve subjects in Oxford. Both priming with RTS,S and boosting MVA-CS, and the reverse, were found to be safe and well tolerated. T cell responses as measured by IFN-γ ex vivo ELISPOT w...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2006-04, Vol.24 (15), p.2850-2859
Main Authors: Dunachie, Susanna J., Walther, Michael, Vuola, Jenni M., Webster, Daniel P., Keating, Sheila M., Berthoud, Tamara, Andrews, Laura, Bejon, Philip, Poulton, Ian, Butcher, Geoffrey, Watkins, Katherine, Sinden, Robert E., Leach, Amanda, Moris, Philippe, Tornieporth, Nadia, Schneider, Joerg, Dubovsky, Filip, Tierney, Eveline, Williams, Jack, Gray Heppner, D., Gilbert, Sarah C., Cohen, Joe, Hill, Adrian V.S.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antibodies, Protozoan - blood
Applied microbiology
Biological and medical sciences
Clinical trial
Clinical trials
Female
Fundamental and applied biological sciences. Psychology
Hepatitis
Human protozoal diseases
Humans
Immunization
Immunization, Secondary
Immunogenicity
Infections
Infectious diseases
Interferon-gamma - biosynthesis
Lymphocytes
Malaria
Malaria - immunology
Malaria - prevention & control
Malaria Vaccines - administration & dosage
Malaria Vaccines - adverse effects
Malaria Vaccines - immunology
Male
Medical sciences
Microbiology
Middle Aged
Parasitic diseases
Plasmodium falciparum
Poxvirus
Proteins
Protozoal diseases
T cells
T-Lymphocytes - immunology
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Vaccinia virus - immunology
Vector-borne diseases
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Heterologous prime-boost immunisation with RTS,S/AS02A and the poxvirus MVA-CS was evaluated in 18 healthy malaria-naïve subjects in Oxford. Both priming with RTS,S and boosting MVA-CS, and the reverse, were found to be safe and well tolerated. T cell responses as measured by IFN-γ ex vivo ELISPOT were induced, but the responses were low to moderate in both groups, with heterologous boosting yielding only small increments in T cell immunogenicity and no increased antibody response. Protection against 3D7 Plasmodium falciparum sporozoite challenge 4 weeks after the final vaccination was equal for both regimens at 33% (95% C.I. 4.3–77.7%), with one subject remaining fully protected on rechallenge at 5 months.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2005.12.041